1452 Seroconversion Rates in Celiac Disease After Hbv Vaccination

Abstract

Celiac disease (CD) is a condition potentially impairing seroconversion against hepatitis B virus (HBV). Methods. We studied retrospectively 81 consecutive CD patients (24 M and 57 F) with a median (interquartile range, IQR) age of 10 (7) yr (range 2-30 yr) and 50 controls (26 M and 24 F) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard anti-HBV vaccination schedule at 3, 5 and 11 months of age. Subjects affected by autoimmune and neoplastic diseases or immunosuppressive treatment where excluded from the study. Results: The median (IQR) interval from the last dose of vaccine was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr, p < 0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6 (1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2- 12.3 yr). A cut-point ≥ 10 mUI/ml for HbsAg title was considered to indicate seroconversion for HBV vaccination. 33/81 CD patients did not seroconverte compared to 10/50 controls (p < 0.05). The Odds ratio of a protective HbsAg title in CD subjects vs controls was 0.36 (95% CI, 0.16-0.83, p < 0.0001) and was not associated with gender, the interval from the last administration of the vaccine nor with the duration of gluten intake in CD patients.